NASDAQ:APRE

Aprea Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy APRE

*Your capital is at risk

$0.83

+0.0344 (+4.33%)

At Close: Jun 23, 2026

Aprea Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 94.54. In total, the insiders bought 1.04M and sold 12.92K APRE shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	94.54
● Buy	1.04M shares
● Sell	12.92K shares
98% Buy Activity Moderate Negative Correlation
Buy Signal High Confidence Mar 31, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 94.54. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (98% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 16, 2026 Buy	Stock Options (Right to Buy) A-Award	Seizinger Bernd R. Director	Director	12 555 Value: $9K
Jun 16, 2026 Buy	Common Stock A-Award	Seizinger Bernd R. Director	Director	3 135 Value: $2K
Jun 16, 2026 Buy	Common Stock A-Award	Pamukcu Rifat Director	Director	3 135 Value: $2K
Jun 16, 2026 Buy	Stock Options (Right to Buy) A-Award	Pamukcu Rifat Director	Director	12 555 Value: $9K
Jun 16, 2026 Buy	Stock Options (Right to Buy) A-Award	Duey Marc Director	Director	12 555 Value: $9K
Jun 16, 2026 Buy	Common Stock A-Award	Duey Marc Director	Director	3 135 Value: $2K
Jun 16, 2026 Buy	Common Stock A-Award	Bizzari Jean-pierre Director	Director	3 135 Value: $2K
Jun 16, 2026 Buy	Stock Options (Right to Buy) A-Award	Bizzari Jean-pierre Director	Director	12 555 Value: $9K
Jun 16, 2026 Buy	Stock Options (Right to Buy) A-Award	Henneman John B Iii Director	Director	12 555 Value: $9K
Jun 16, 2026 Buy	Stock Options (Right to Buy) A-Award	Grissinger Michael Director	Director	12 555 Value: $9K
Jun 16, 2026 Buy	Common Stock A-Award	Grissinger Michael Director	Director	3 135 Value: $2K
Jun 16, 2026 Buy	Stock Options (Right to Buy) A-Award	Gruia Gabriela Director	Director	12 555 Value: $9K
Jun 16, 2026 Buy	Common Stock A-Award	Gruia Gabriela Director	Director	3 135 Value: $2K
Jun 16, 2026 Buy	Stock Options (Right to Buy) A-Award	Peters Richard Director	Director	12 555 Value: $9K
Jun 16, 2026 Buy	Common Stock A-Award	Peters Richard Director	Director	3 135 Value: $2K
Jun 16, 2026 Buy	Common Stock A-Award	Henneman John B Iii Director	Director	3 135 Value: $2K
Mar 31, 2026 Buy	Pre-Funded Warrant P-Purchase	Hamill John P. Srvp/cfo/prin Fin & Acct Ofcr	C-Suite Officer	30 978 Value: $31
Mar 31, 2026 Buy	Common Warrant P-Purchase	Hamill John P. Srvp/cfo/prin Fin & Acct Ofcr	C-Suite Officer	30 978 Value: $21.2K
Mar 31, 2026 Buy	Pre-Funded Warrant P-Purchase	Peters Richard Director	Director	123 915 Value: $124
Mar 31, 2026 Buy	Common Warrant P-Purchase	Peters Richard Director	Director	123 915 Value: $84.6K
Mar 12, 2026 Buy	Common Stock A-Award	Hamill John P. Srvp/cfo/prin Fin & Acct Ofcr	C-Suite Officer	10 095 Value: $8K
Mar 12, 2026 Buy	Stock Options (Right to Buy) A-Award	Gilad Oren President/ceo	CEO / President	80 700 Value: $61.7K
Mar 12, 2026 Buy	Common Stock A-Award	Gilad Oren President/ceo	CEO / President	20 175 Value: $15.4K
Mar 12, 2026 Buy	Stock Options (Right to Buy) A-Award	Hamill John P. Srvp/cfo/prin Fin & Acct Ofcr	C-Suite Officer	40 380 Value: $30.9K
Jan 30, 2026 Buy	Common Stock P-Purchase	Gilad Oren President/ceo	CEO / President	28 100 Value: $25.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT APREA THERAPEUTICS INC.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATR...

Read Full Profile Here